DE69434820D1 - Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis - Google Patents
Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitisInfo
- Publication number
- DE69434820D1 DE69434820D1 DE69434820T DE69434820T DE69434820D1 DE 69434820 D1 DE69434820 D1 DE 69434820D1 DE 69434820 T DE69434820 T DE 69434820T DE 69434820 T DE69434820 T DE 69434820T DE 69434820 D1 DE69434820 D1 DE 69434820D1
- Authority
- DE
- Germany
- Prior art keywords
- vector
- gene
- vaccine
- nucleic acid
- compound containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108020004635 Complementary DNA Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 101150010882 S gene Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000010804 cDNA synthesis Methods 0.000 abstract 1
- 230000001112 coagulating effect Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9312659A FR2711670B1 (fr) | 1993-10-22 | 1993-10-22 | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
FR9312659 | 1993-10-22 | ||
PCT/FR1994/000483 WO1995011307A1 (fr) | 1993-10-22 | 1994-04-27 | Vecteur nucleotidique, composition le contenant et vaccin pour l'immunisation a l'encontre d'une hepatite |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69434820D1 true DE69434820D1 (de) | 2006-09-21 |
DE69434820T2 DE69434820T2 (de) | 2007-03-29 |
DE69434820T3 DE69434820T3 (de) | 2011-02-24 |
Family
ID=9452149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69434820T Expired - Lifetime DE69434820T3 (de) | 1993-10-22 | 1994-04-27 | Nukleinsäurevektor, einen solchen Vektor enthaltene Verbindung und Impfstoff zur Immunisierung gegen Hepatitis |
Country Status (11)
Country | Link |
---|---|
US (2) | US6635624B1 (de) |
EP (1) | EP0724642B2 (de) |
AT (1) | ATE335831T1 (de) |
AU (1) | AU6681794A (de) |
CA (1) | CA2174652C (de) |
DE (1) | DE69434820T3 (de) |
DK (1) | DK0724642T4 (de) |
ES (1) | ES2270416T5 (de) |
FR (1) | FR2711670B1 (de) |
PT (1) | PT724642E (de) |
WO (1) | WO1995011307A1 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2711670B1 (fr) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5837534A (en) * | 1995-11-14 | 1998-11-17 | The Board Of Regents Of The University Of Texas System | Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells |
US5981274A (en) * | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
EP0855184A1 (de) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung |
CN1044092C (zh) | 1997-02-26 | 1999-07-14 | 上海医科大学 | 抗原-抗体-重组dna复合型疫苗 |
FR2767337B1 (fr) | 1997-08-14 | 2002-07-05 | Pasteur Institut | Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
WO1999028475A2 (en) | 1997-11-28 | 1999-06-10 | Genset | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US20040062775A1 (en) | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
US6759193B2 (en) | 1999-07-28 | 2004-07-06 | The Government Of The Republic Of Singapore | Detection of human hepatitis B virus surface antigen mutants by specific amplification and its application on gene chip |
EP1311288A1 (de) * | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunstimulierende nukleinsäuren zur induktion einer th-2 immunreaktion |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US7001760B2 (en) * | 2000-04-20 | 2006-02-21 | Wang-Schick Ryu | Hepatitis B virus vectors for gene therapy |
JP2006515277A (ja) * | 2002-10-29 | 2006-05-25 | コーリー ファーマシューティカル グループ, リミテッド | C型肝炎ウィルス感染の処置および予防に関する方法および製品 |
WO2004087203A2 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
KR20060016817A (ko) * | 2003-06-20 | 2006-02-22 | 콜리 파마슈티칼 게엠베하 | 소분자 톨-유사 수용체 (tlr) 길항제 |
CN1704475A (zh) * | 2004-05-31 | 2005-12-07 | 成都生物制品研究所 | 羧端含前s2免疫决定簇的乙肝表面抗原融合基因及蛋白质 |
WO2006077266A1 (en) | 2005-01-24 | 2006-07-27 | Laboratoires Serono S.A. | Use of soluble cd164 variants in inflammatory and/or autoimmune disorders |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物 |
AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
ES2689878T3 (es) | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
US9987348B2 (en) | 2013-09-25 | 2018-06-05 | Zoetis Services Llc | PCV2B divergent vaccine composition and methods of use |
KR20160132494A (ko) | 2014-04-03 | 2016-11-18 | 베링거잉겔하임베트메디카인코퍼레이티드 | 돼지 유행성 설사 바이러스 백신 |
BR112017028224A2 (pt) | 2015-08-31 | 2018-09-11 | Boehringer Ingelheim Vetmedica Gmbh | composição, e, método para proteger um leitão contra uma doença associada a pestivírus. |
AU2016323106A1 (en) | 2015-09-16 | 2018-03-29 | Boehringer Ingelheim Animal Health USA Inc. | Salmonella Choleraesuis-Salmonella Typhimurium vaccines |
CN109715219B (zh) | 2016-09-20 | 2024-03-01 | 勃林格殷格翰动物保健有限公司 | 犬腺病毒载体 |
CA3036293A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
EP3515480A1 (de) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | Neuer schweinegrippenimpfstoff |
UY37406A (es) | 2016-09-20 | 2018-03-23 | Boehringer Ingelheim Vetmedica Gmbh | Nuevo sitio de inserción orf70 de ehv |
MX2019005136A (es) | 2016-11-03 | 2019-06-20 | Boehringer Ingelheim Vetmedica Gmbh | Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta. |
KR102669319B1 (ko) | 2016-11-03 | 2024-05-28 | 베링거잉겔하임베트메디카게엠베하 | 돼지 파보바이러스에 대한 백신 |
WO2018140766A2 (en) | 2017-01-30 | 2018-08-02 | Boehringer Ingelheim Vetmedica, Inc. | Porcine coronavirus vaccines |
CA3068052A1 (en) | 2017-07-12 | 2019-01-17 | Boheringer Ingelheim Animal Health Usa Inc. | Senecavirus a immunogenic compositions and methods thereof |
KR20200057742A (ko) | 2017-09-23 | 2020-05-26 | 베링거잉겔하임베트메디카게엠베하 | 파라믹소바이러스과 발현 시스템 |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
CN111712575B (zh) | 2018-02-23 | 2024-07-19 | 勃林格殷格翰动物保健有限公司 | 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗 |
CN111867625A (zh) | 2018-03-19 | 2020-10-30 | 勃林格殷格翰动物保健有限公司 | 具有失活ul18和/或ul8的新ehv |
MX2020009722A (es) | 2018-03-19 | 2021-01-29 | Boehringer Ingelheim Vetmedica Gmbh | Nuevo sitio de insercion ul43 de ehv. |
CA3091982A1 (en) | 2018-03-26 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
EP3852800A1 (de) | 2018-09-20 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Intranasaler vektorimpfstoff gegen epidemische virusdiarrhoe |
WO2020058327A1 (en) | 2018-09-20 | 2020-03-26 | Boehringer Ingelheim Vetmedica Gmbh | Modified pedv spike protein |
WO2021158878A1 (en) | 2020-02-06 | 2021-08-12 | Boehringer Ingelheim Animal Health USA Inc. | Polypeptides useful for detecting anti-rhabdovirus antibodies |
CA3195910A1 (en) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
US20220160864A1 (en) | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
US20240050555A1 (en) | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US565203A (en) | 1896-08-04 | espersen | ||
IN151589B (de) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
DE2942780A1 (de) | 1979-10-23 | 1981-05-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte |
US4803164A (en) | 1981-08-31 | 1989-02-07 | Genentech, Inc. | Preparation of hepatitis b surface antigen in yeast |
US4547367A (en) | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis B core antigen vaccine |
FR2560890B1 (fr) | 1984-03-07 | 1987-10-16 | Grp Genie Genetique | Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention |
JPS6137738A (ja) | 1984-07-31 | 1986-02-22 | Tetsuo Nakamura | B型肝炎ワクチン |
BR8404286A (pt) * | 1984-08-28 | 1986-04-08 | Sergio Landau | Seringa hipodermica a pressao |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
CA1268437A (en) | 1984-12-21 | 1990-05-01 | Haruo Fujita | Method for purification of hbc antigen and method for measurement of hbc antibody by using said purified hbc antigen |
US4957869A (en) | 1985-07-12 | 1990-09-18 | New York University | Immunogenic peptide corresponding to P. vivax CS protein |
WO1988006185A1 (en) * | 1987-02-11 | 1988-08-25 | Scripps Clinic And Research Foundation | Retroviral expression vectors and methods for producing hbv antigens |
US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
US5256553A (en) | 1987-10-09 | 1993-10-26 | Immunex Corporation | Multiple promoter transforming retroviral vectors |
ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
EP0502179A1 (de) * | 1990-09-28 | 1992-09-09 | Smithkline Beecham Corporation | Erhöhte expression von viralen proteinen in drosophila zellen |
CA2086831C (en) | 1991-05-08 | 1999-03-16 | Reinhard Gluck | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
WO1993000103A1 (en) | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
HU209110B (en) | 1991-12-02 | 1994-03-28 | Foeldtani Kutato Es Furo Kft | Process for the local treatment of soil, particularly for the examination and cleaning of contaminated soil |
ATE219522T1 (de) | 1992-02-04 | 2002-07-15 | Chiron Corp | Hepatistherapeutikum |
GB9204274D0 (en) * | 1992-02-28 | 1992-04-08 | Wellcome Found | Novel peptides |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
JPH09501936A (ja) | 1993-08-26 | 1997-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 |
FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
US5814617A (en) | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US5565023A (en) * | 1995-11-15 | 1996-10-15 | Fusion All-Sport Grip, Inc. | Moisture absorbing and frictional grip enhancing composition and method of forming same |
CA2244946C (en) | 1996-01-30 | 2010-04-13 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US20070031446A1 (en) | 2003-07-11 | 2007-02-08 | Intercell Ag | Hcv vaccines |
CA2405424A1 (en) | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
WO2005039633A1 (de) | 2003-10-24 | 2005-05-06 | Mologen Ag | Mittel zur behandlung von infektionen mit leishmanien |
-
1993
- 1993-10-22 FR FR9312659A patent/FR2711670B1/fr not_active Expired - Lifetime
-
1994
- 1994-04-27 DE DE69434820T patent/DE69434820T3/de not_active Expired - Lifetime
- 1994-04-27 WO PCT/FR1994/000483 patent/WO1995011307A1/fr active IP Right Grant
- 1994-04-27 AU AU66817/94A patent/AU6681794A/en not_active Abandoned
- 1994-04-27 EP EP19940914452 patent/EP0724642B2/de not_active Expired - Lifetime
- 1994-04-27 AT AT94914452T patent/ATE335831T1/de active
- 1994-04-27 ES ES94914452T patent/ES2270416T5/es not_active Expired - Lifetime
- 1994-04-27 DK DK94914452T patent/DK0724642T4/da active
- 1994-04-27 CA CA 2174652 patent/CA2174652C/fr not_active Expired - Lifetime
- 1994-04-27 PT PT94914452T patent/PT724642E/pt unknown
-
1998
- 1998-09-02 US US09/146,072 patent/US6635624B1/en not_active Expired - Lifetime
-
2003
- 2003-08-20 US US10/644,267 patent/US7825097B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2270416T5 (es) | 2010-11-30 |
DE69434820T3 (de) | 2011-02-24 |
DE69434820T2 (de) | 2007-03-29 |
ATE335831T1 (de) | 2006-09-15 |
DK0724642T3 (da) | 2006-12-18 |
US6635624B1 (en) | 2003-10-21 |
CA2174652C (fr) | 2010-03-30 |
AU6681794A (en) | 1995-05-08 |
CA2174652A1 (fr) | 1995-04-27 |
ES2270416T3 (es) | 2007-04-01 |
PT724642E (pt) | 2006-12-29 |
DK0724642T4 (da) | 2010-10-25 |
FR2711670A1 (fr) | 1995-05-05 |
US20050042203A1 (en) | 2005-02-24 |
WO1995011307A1 (fr) | 1995-04-27 |
EP0724642B2 (de) | 2010-07-21 |
US7825097B2 (en) | 2010-11-02 |
FR2711670B1 (fr) | 1996-01-12 |
EP0724642A1 (de) | 1996-08-07 |
EP0724642B1 (de) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434820D1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
CA2210353A1 (en) | Stabilized external guide sequences | |
DE68929343D1 (de) | Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen | |
BR0010725A (pt) | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc | |
BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
DE69636032D1 (de) | Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren | |
FI934937A (fi) | Sekvenser av hcv-genom foer diagnostisk och terapi | |
DE69737886D1 (de) | Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays | |
AU1634092A (en) | Vaccines and methods for their production | |
WO1995003414A3 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor | |
KR930701610A (ko) | 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법 | |
ATE310747T1 (de) | Impfstoff gegen geflügelkokzidose | |
EP0256677A3 (de) | Pseudorabiesvirus-Rekombinanten und ihre Verwendung zur Herstellung von Proteinen | |
EP0227604A3 (de) | Verwendung von Oligopeptiden in der Behandlung von viralen Infektionen | |
AU7514087A (en) | Vaccine containing the protein f of the aids virus | |
AU686000B2 (en) | Infectious peritonitis vaccine | |
ATE209683T1 (de) | Planze resistent gegen mindestens zwei viren und dessen preparation | |
IL146191A0 (en) | Viral expression vectors | |
AU6111294A (en) | Composition for use in the treatment of tumours and the immunization of humans and animals | |
DE69939212D1 (de) | Polypeptid mit aktivität gegen das humane immundefizienz virus, dafür kodierende gene und verfahren zur herstellung des polypeptids | |
HUP0103871A2 (hu) | Rekombináns CELO-vírus és CELO vírus DNS | |
ES2367245T8 (es) | Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo. | |
EP0789563B8 (de) | Impfstoffe gegen den hepatitis b und c virus | |
TH1348A (th) | การประดิษฐ์ไวรัสที่มีโปรตีนพื้นผิวเป็นรีคอมบิแนนท์โปรตีน | |
TH63069A (th) | โคลนก่อการติดเชื้อ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings |